Clinical trial
Persistence of Antibody Response to N. Meningitidis Group C in Children
NCT00316654 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00316654 |
|---|---|
| Title | Persistence of Antibody Response to N. Meningitidis Group C in Children |
| Official title | A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate… |
| Lead sponsor | Novartis Vaccines, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prevention of Meningococcal Infection |
| Intervention type | Biological |
| Interventions | Meningococcal C conjugate vaccine |
| Enrollment | 489 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Apr 21, 2006 |
| Last update posted | Jul 25, 2017 |
| Countries | Poland, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: